Abstracts tagged "Interleukins (IL) and quality of life"

Abstract Number: 318 • ACR/ARHP Annual Meeting 2013
Effect Of Brodalumab (AMG 827) On Pain and Physical Functioning In Patients With Psoriatic Arthritis
MC Genovese¹, Philip J. Mease², Hema Viswanathan³, Dina Chau³, JingYuan Feng³, Ngozi Erondu³ and Ajay Nirula³, ¹Stanford University, Palo Alto, CA, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Amgen Inc, Thousand Oaks, CA
Background/Purpose: Psoriatic arthritis (PsA) has a significant impact on health related quality of life (HRQoL). This analysis evaluated the efficacy of brodalumab, a human anti-IL-17…
Abstract Number: 269 • ACR/ARHP Annual Meeting 2013
Marked Improvement In Patient Reported Outcomes Of Children With Active Systemic Juvenile Idiopathic Arthritis With Canakinumab Treatment – Results Of The Phase III Program
Rayfel Schneider¹, Hermine Brunner¹, Nicolino Ruperto², Nico Wulffraat², Pierre Quartier³, Riva Brik², Liza McCann², Helen E. Foster², Michael Frosch², Valeria Gerloni², Liora Harel², Claudio Len², Kristin Houghton¹, Rik Joos², Ken Abrams⁴, Karine Lheritier⁵, Sophia Kessabi⁵, Alberto Martini² and Daniel J. Lovell¹, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Efficacy and safety of canakinumab (CAN), a selective, fully human, anti-interleukin-1β monoclonal antibody, in systemic juvenile idiopathic arthritis (SJIA) patients has been demonstrated in…